Advances in the study of the relationship between β<sub>2</sub>-glycoprotein I/ox-LDL immune complexes and vascular disease in antiphospholipid syndrome

Home > Archive>Volume 25, Issue 12, 2017 >1273-1279

Advances in the study of the relationship between β2-glycoprotein I/ox-LDL immune complexes and vascular disease in antiphospholipid syndrome
DOI:
                        
                    
CSTR:
                        
                    
Author:
                        YU Cheng-JieYU Cheng-Jie
Key Laboratory of Glucolipid Metabolism in Liaoning Province & College of Life Science and Technology, Dalian University, Dalian, Liaoning 116600, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LI Jing-DaLI Jing-Da
Key Laboratory of Glucolipid Metabolism in Liaoning Province & College of Life Science and Technology, Dalian University, Dalian, Liaoning 116600, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
LIU Qing-PingLIU Qing-Ping
Key Laboratory of Glucolipid Metabolism in Liaoning Province & College of Life Science and Technology, Dalian University, Dalian, Liaoning 116600, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Key Laboratory of Glucolipid Metabolism in Liaoning Province & College of Life Science and Technology, Dalian University, Dalian, Liaoning 116600, China)
Clc Number:R393.32
Fund Project:

Article

Figures

Metrics

Reference [50]

Cited by

Materials

Comments

Abstract:

sub>2-glycoprotein I (β₂-GPI), a main autoantigen in patients with antiphospholipid syndrome (APS), binds to the negative lipid components, such as oxidized low density lipoprotein (ox-LDL) and cardiolipin, thereby forming a stable β₂-GPI immune complex. β₂-GPI immune complexes and the immune response induced by anti-β₂-GPI immune complex antibodies significantly promote the formation of atherosclerotic plaques and vascular injury in patients with antiphospholipid syndrome. This review summarized the formation mechanism and the effects of β₂-glycoprotein I immune complex and the effect of β₂-glycoprotein I immune complex in the pathogenic process. The mechanism of β₂-GPI-DⅤ blocking the formation of β₂-GPI/ox-LDL complex was introduced, which provided possible drug targets and therapeutic ideas for cardiovascular diseases, especially atherosclerosis, caused by β₂-GPI/ox-LDL immune complex.

Key words:β₂-glycoprotein I; Oxidized low density lipoprotein; Antiphospholipid syndrome; Atherosclerosis

Reference

[1] Serrano F.Antiphospholipid syndrome:A complex disease.J Nephropathol, 3,2(1):73-74.

[2] Hughes GRV, Phillips H.Mycophenolate mofetil and cardiovascular disease.Lupus, 6,5(11 suppl):1-2.

[3] van Leuven SI, Kastelein JJ, D′Cruz D P, et al.Atherogenesis in rheumatology.Lupus, 6,5(3):117-121.

[4] Matsuura E, Kobayashi K, Inoue K, et al.Oxidized LDL/β₂-glycoprotein I complexes:new aspects in atherosclerosis.Lupus, 5,4(9):736-741.

[5] Berger JS, Rockman CB, Guyer KE, et al.Proatherogenicoxidized low-density lipoprotein/β₂-glycoprotein I complexes in arterial and venous disease.J Immunol Res, 4,4(234316):1 115-165.

[6] Zhang X, Xie Y, Zhou H, et al.Involvement of TLR4 in oxidized LDL/β₂GPI/anti-β₂GPI-induced transformation of macrophages to foam cells.J Atheroscler Thromb, 4,1(11):1 140-151.

[7] Liu YM, Zhang WY, Wang ZF, et al.High expression of beta2-glycoprotein I is associated significantly with the earliest stages of hepatitis B virus infection.J Med Virol, 4,6(8):1 296-306.

[8] Stefas I, Tigrett S, Dubois G, et al.Interactions betweenhepatitis C virus and the human apolipoprotein H acute phase protein:A tool for a sensitive detection of the virus.PLoS One, 5,0(10):e0140900.

[9] Ferluga J, Kishore U, Sim RB.A potential anti-coagulant role of complement factor H.Mol Immunol, 4,9(2):188-193.

[10] Betts NA, Ahuja KD, Adams MJ.Anti-β₂GP1 antibodies have variable effects on platelet aggregation.Pathology, 3,5(45):155-161.

[11] De LB, Eckmann CM, Van SM, et al.Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.Blood Coagul Fibrinolysis, 8,9(8):757-764.

[12] Giannakopoulos B, Mirarabshahi P, Krilis SA.New insights into the biology and pathobiology of beta2-glycoprotein I.Curr Rheumatol Rep, 1,3(1):90-95.

[13] 汪玮琳.还原型β₂糖蛋白I抑制ox-LDL诱导巨噬细胞泡沫化和凋亡的研究.天津:天津医科大学, 2014.

[14] El-Assaad F, Krilis SA, Giannakopoulos B.Posttranslational forms of beta 2-glycoprotein I in the pathogenesis of the antiphospholipid syndrome.Thromb J, 6,4(Suppl 1):20.

[15] Chamorro AJ, Marcos M, Mirón-Canelo JA, et al.Val247Leu β2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome:systematic review and meta-analysis.Autoimmun Rev, 2,1(10):705-712.

[16] Núez-lvarez CA, Hernández-Ramírez DF, Martinez-Castillo A, et al.Cellular immune response to β₂-glycoprotein-I valine/leucine(247) phenotypes in Mexican patients with primary antiphospholipid syndrome.Hum Immunol, 7,8(2):146-152.

[17] Mehdi H, Naqvi A, Kamboh MI.Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H).Biochim Biophys Acta, 8,2(3):163-168.

[18] Agar C, van Os G M, Mrgelin M, et al.Beta2-glycoprotein I can exist in 2 conformations:implications for our understanding of the antiphospholipid syndrome.Blood, 0,6(8):1 336-343.

[19] Sakellarios AI, Papafaklis MI, Siogkas P, et al.Patient-specific computational modeling of subendothelial LDL accumulation in a stenosed right coronary artery:effect of hemodynamic and biological factors.Am J Physiol Heart Circ Physiol, 3,4(11):1 455-470.

[20] 刘庆平.动脉粥样硬化与自身免疫.北京:化学工业出版社, 2010; 5.

[21] Weber C, Noels H.Atherosclerosis:current pathogenesis and therapeutic options.Nat Med, 1,7(11):1 410-422.

[22] 张鹤, 刘庆平.氧化型低密度脂蛋白的致病性及检测方法研究进展.中国动脉硬化杂志, 6,4(6):633-638.

[23] Lopez D, Garcia-Valladares I, Palafox-Sanchez CA, et al.Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies to oxLig-1/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome.Am J Clin Pathol, 4,1(3):426-436.

[24] Kobayashi K, Kishi M, Atsumi T, et al.Circulating oxidized LDL forms complexes with β₂-glycoprotein I implication as an atherogenic autoantigen.J Lipid Res, 3,4(4):716-726.

[25] Rahgozar S, Yang Q, Giannakopoulos B, et al.Beta2-glycoprotein I binds thrombin via exosite I and exosite II:Anti-β₂-glycoprotein I antibodies potentiate the inhibitory effect of β₂-glycoprotein I on thrombin-mediated factor XIa generation.Arthritis Rheum, 7,6(2):605-613.

[26] Kuwana M, Matsuura E, Kobayashi K, et al.Binding of beta2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells.Blood, 5,5(4):1 552-557.

[27] Pengo V, Ruffatti A, Tonello M, et al.Antiphospholipid syndrome:antibodies to Domain 1 of β₂-glycoprotein 1 correctly classify patients at risk.J Thromb Haemost, 5,3(5):782-787.

[28] De Craemer AS, Musial J, Devreese KM.Role of anti-domain 1-β₂ glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome.J Thromb Haemost, 6,4(9):1 779-787.

[29] Sorice M, Buttari B, Capozzi A, et al.Antibodies to age-β₂ glycoprotein I in patients with antiphospholipid antibody syndrome.Clin Exp Immunol, 6,4(2):174-182.

[30] Liu Q, Kobayashi K, Furukawa J, et al.Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for beta2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages.J Lipid Res, 2,3(9):1 486-495.

[31] Majka DS, Liu K, Pope RM, et al.Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults(CARDIA) cohort.Inflamm Res, 3,2(10):919-927.

[32] Kobayashi K, Kishi M, Atsumi T, et al.Circulating oxidized LDL forms complexes with β₂-glycoprotein I.Metabolites, 3,5(2):252-269.

[33] Lopez LR, Salazar-Paramo M, Palafox-Sanchez C, et al.Oxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness:implications in autoimmune-mediated atherosclerosis.Lupus, 6,5(2):80-86.

[34] Matsuura E, Lopez LR.Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis.Clin Dev Immunol, 4,1(2):103-111.

[35] Bliden KP, Chaudhary R, Lopez LR, et al.Oxidized low-density lipoprotein-β₂-glycoprotein I complex but not free oxidized LDL is associated with the presence and severity of coronary artery disease.Am J Cardiol, 6,8(5):673-678.

[36] Matsuura E, Lopez LR, Shoenfeld Y, et al.β₂-glycoprotein I and oxidative inflammation in early atherogenesis:a progression from innate to adaptive immunity.Autoimmun Rev, 2,2(2):241-249.

[37] Amézaga N, Sanjurjo L, Julve J, et al.Human scavenger protein AIM increases foam cell formation and CD36-mediated ox-LDL uptake.J Leukoc Biol, 4,5(3):509-520.

[38] Liu W, Yin Y, Zhou Z, et al.ox-LDL-induced IL-1beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation.Inflamm Res, 4,3(1):33-43.

[39] Takao K.Antiphospholipid syndrome:30 years and our contribution.Int J Rheum Dis, 5,8(2):233-241.

[40] Rajamki K, Lappalainen J, Orni K, et al.Cholesterol crystals activate the NLRP3 inflammasome in human macrophages:a novel link between cholesterol metabolism and inflammation.PLoS One, 2,5(7):e11765.

[41] Zhao R, Zhou H, Su SB.A critical role for interleukin-1β in the progression of autoimmune diseases.Int Immunopharmacol, 3,7(3):658-669.

[42] Xu Y, Kong X, Zhou H, et al.ox-LDL/β2GPI/anti-β2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway.Thromb Res, 4,4(2):384-392.

[43] Zhang Y, Li W, Chi Y, et al.Recombinant domain Ⅴ of β₂-glycoprotein I inhibits the formation of a 7-ketocholesteryl-9-carboxynonanoate and β₂-glycoprotein I complex.J Biochem, 1,9(1):35-42.

[44] Li J, Chi Y, Liu S, et al.Recombinant domain Ⅴ of β₂-glycoprotein I inhibits the formation of atherogenic ox-LDL/β₂-glycoprotein I complexes.J Clin Immunol, 4,4(6):669-676.

[45] Wang WL, Meng ZX, Zhou SJ, et al.Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis.Lipids Health Dis, 3,2:174.

[46] Peterson LK, Willis R, Harris EN, et al.Antibodies to phosphatidylserine/prothrombin complex in antiphospholipid syndrome:Analytical and clinical perspectives.Adv Clin Chem, 6,3(1):1-28.

[47] Meroni PL.Anti-beta-2 glycoprotein I epitope specificity:from experimental models to diagnostic tools.Lupus, 6,5(8):905-910.

[48] Pengo V, Hoxha A, Ruffatti A.Diagnosis and therapy of antiphospholipid syndrome.Author's reply.Pol Arch Med Wewn, 5,5(10):785-786.

[49] Erkan D, Lockshin MD.APS action-antiphospholipid syndrome alliance for clinical trials and international networking..Lupus, 2,1(7):695-698.

[50] Barbhaiya M, Andrade D, Erkan D, et al.Antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION):5-Year Update.Curr Rheumatol Rep, 6,8(10):64.

Get Citation

YU Cheng-Jie, LI Jing-Da, LIU Qing-Ping. Advances in the study of the relationship between β₂-glycoprotein I/ox-LDL immune complexes and vascular disease in antiphospholipid syndrome[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2017,25(12):1273-1279.

Copy

Article Metrics

Abstract:1337
PDF: 881
HTML: 0
Cited by: 0

History

Received:March 23,2017
Revised:April 12,2017
Adopted:
Online: December 28,2017
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code